(Q39305589)

10 September 2017

title

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells (English)

1 reference

chronic lymphocytic leukemia

10 September 2017

0 references

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

1 reference

Clemens-Martin Wendtner

7

object named as

Clemens-Martin Wendtner

1 reference

10 September 2017

8

Michael Hallek

1 reference

10 September 2017

Mirjam Kuckertz

1

1 reference

10 September 2017

Michaela Patz

2

1 reference

10 September 2017

Aditya Veldurthy

3

1 reference

10 September 2017

Iris Gehrke

4

1 reference

10 September 2017

Julia Claasen

5

1 reference

10 September 2017

Lukas P Frenzel

6

1 reference

10 September 2017

Günter Krause

9

1 reference

10 September 2017

publication date

6 July 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

35

1 reference

10 September 2017

issue

7-8

1 reference

10 September 2017

page(s)

420-426

1 reference

Chronic lymphocytic leukemia: revelations from the B-cell receptor.

10 September 2017

cites work

1 reference

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

21 January 2018

1 reference

Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib

21 January 2018

1 reference

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

21 January 2018

1 reference

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

21 January 2018

1 reference

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

21 January 2018

1 reference

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress

21 January 2018

1 reference

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

Measuring and interpreting the selectivity of protein kinase inhibitors

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

21 January 2018

1 reference

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals

21 January 2018

1 reference

Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.

21 January 2018

1 reference

Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.

21 January 2018

1 reference

Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000341081

1 reference

10 September 2017

1 reference